Focusing on breast cancer overdiagnosis and overtreatment: The promise of molecular medicine

Breast Journal

Volumn 19, Issue 2, 2013, Pages 127-129

  Masood, Shahla ^a  

^a Breast Journal Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER PREVENTION; CANCER REGISTRY; CANCER SCREENING; CANCER THERAPY; CLINICAL PRACTICE; DNA MICROARRAY; EARLY DIAGNOSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MOLECULAR MEDICINE; REVIEW; SCREENING MAMMOGRAPHY;

ADULT; BREAST; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; MOLECULAR MEDICINE; UNITED STATES;

EID: 84874744883     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12095     Document Type: Review

References (15)

1. Mandelblatt JS, Cronin KA, Bailey S, et al,. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009; 151: 738-47.
2. Bleyer A, Welch HG,. Effect of three decades of screening mammography on breast cancer incidence. N Engl J Med. 1998 -2005; 367: 21.
3. Masood S,. Is it time to retire the term of "in situ carcinoma" and use the term of "borderline breast disease"? Breast J 2010; 16: 571-2.
4. Allred C,. Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr 2010; 41: 134-8.
5. Saul S,. Earliest steps to find breast cancer area prone to error. New York Times, 20 July 2010, p. A1.
6. Allegra CJ, Aberle DR, Ganschow P, et al,. National institutes of health state-of the science conference statement: diagnosis and management of ductal carcinoma in situ. September 22-24, 2009. J Natl Cancer Inst 2010; 102: 161-9.
7. Masood S, Rosa M,. Boarderline breast lesions; diagnostic challenges and clinical implication. Adv. Anat. Pathol. 2011; 18: 190-8.
8. Masood S,. Why the term "low-grade ductal carcinoma insitu" should be changed to "borderline breast disease": diagnostic and clinical implications. Women's Health 2012; 8: 57-62.
9. van't Veer LJ, Dai H, van de Vijver MJ, et al,. Expression profiling predicts outcome in breast cancer. Breast Cancer Res 2003; 5: 57-8.
10. Quackenbush J,. Microarray analysis and tumor classification. N Engl J Med 2006; 352: 2463-72.
11. Perous C, Serlie T, Eisen M, et al,. Molecular portraits of human breast tumors. Nature 2000; 406: 747-52.
12. Sotiriou C, Neo SY, McShane LM, et al,. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-8.
13. Nielsen TO, Hsu FD, Jensen K, et al,. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74.
14. Calza S, Hall P, Auer G, et al,. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 2006; 8: R34.
15. Knudsen ES, Pajak TF, Qeenan M, et al,. Retinoblastoma and phosphate and tensin homolog tumor suppressors; Impact on ductal carcinoma in situ progression. J Natl Cancer Inst 2012; 104: 1825-36.